Articles tagged with Cancer Stem Cells
Researchers from FEFU and international partners discover potential targets for glioblastoma multiforme treatment by studying proteins in the WNT signaling pathway. The findings could lead to improved antitumor therapy outcome through suppression of cancer stem cells, accelerating tumor growth rate.
Researchers at Tel Aviv University developed a novel biosensor that can isolate and target leukemic stem cells, the most malignant of all leukemic cells. The sensor uses genetic encoding to identify and characterize these cells, which have high regenerative potential and escape targeted therapies.
Cancer stem-cells are responsible for recurrence and drug resistance. MTHFD2, a mitochondrial metabolic enzyme, plays a critical role in maintaining CSCs by consuming AICAR, leading to depletion of the intracellular pool. Targeting MTHFD2 may eradicate tumors and prevent recurrence.
Researchers found the immune system plays a crucial role in maintaining healthy intestinal stem cells and preventing bowel cancer by enhancing DNA repair mechanisms. The study discovered that cells of the innate immune system can recognize genotoxic environmental factors, such as glucosinolates, and send signals to epithelial stem cell...
Researchers at Kanazawa University have discovered a critical signaling pathway that drives the proliferation of cancer stem cells in breast cancer. The pathway, involving Semaphorin 3 and MICAL3 proteins, is targeted by inhibiting these proteins to reduce breast-cancer stem-like cells.
Researchers discover ADAR1 enzyme promotes cancer cell resistance to treatment by hyper-mutating tumor suppressor RNAs. This enzyme may provide a molecular radar for early detection of malignancies and represent a new therapeutic target for preventing cancer cell resistance.
A new epigenetic therapy targeting enzyme G9a boosts cancer stem cells that drive adenocarcinoma in mice, but also identifies a strategy reducing these cells. Researchers now explore demethylase inhibitors as potential therapeutic drugs to curb lung cancer progression.
Researchers at Kanazawa University identify osteopontin as a key player in HCV replication and stemness in cancer stem cells. The study reveals that osteopontin regulates HCV replication, tumor initiation, and metastasis through the OPN-CD44 axis.
A recent study found that cancer stem cells rely on amino acids for energy, rather than glucose, and this difference makes them susceptible to targeting without harming healthy cells. Researchers have already shown promise with this approach in clinical trials against acute myeloid leukemia, with potential applications to other cancers.
A study in mice suggests that targeting pre-cancerous stem cells could prevent bowel cancer in people with familial adenomatous polyposis (FAP), a condition that increases the risk of developing the disease. Researchers found that treating these stem cells with existing cancer drugs, such as cisplatin, can halt tumour development.
Researchers have discovered a new combination treatment targeting pre-leukemia stem cells by inhibiting protein synthesis and oxidative phosphorylation pathways. The treatment, involving FDA-approved drugs omacetaxine and venetoclax, has shown promising results in killing cancerous cells while leaving healthy stem cells unharmed.
Researchers at McMaster University have identified a previously unknown cell population that triggers the return of acute myeloid leukemia after remission. This discovery provides a potential new target for therapies and offers hope for improving treatment outcomes for patients with leukemia.
Researchers at Duke-NUS Medical School discovered that gut stem cells have a unique population of cells with intrinsic toxin resistance, enabling them to withstand drugs and spicy foods. These 'drug efflux pumps' protect the gut from toxic compounds, promoting intestinal regeneration and overall health.
Researchers developed a novel polymer conjugate to deliver anticancer drugs directly to cancer stem cells, significantly reducing tumor size. The combined use of standard anticancer drugs further enhanced the effect.
Researchers developed a molecular probe to detect cancer stem cells in their native environment. The AlDeSense probe illuminates these cells, allowing them to be identified, tracked, and studied in live mice.
Researchers at Johns Hopkins Medicine have successfully delivered nano-size packets of genetic code called microRNAs to treat human brain tumors implanted in mice. The contents of the super-small containers were designed to target cancer stem cells, a kind of cellular
Researchers have found that cancer stem cells exist in multiple states and can change form, making them resistant to treatment. By targeting cell metabolism, they may be able to kill these stem cells, potentially opening up a new approach to cancer therapy.
Lund University researchers have developed a fluorescent variant of salinomycin to understand its mechanism against cancer stem cells. The molecule rapidly passes through the outer cell membrane and acts as an ion transporter in the endoplasmic reticulum, leading to a reduction in cancer stem cells
Researchers have discovered that acyclic retinoid targets EpCAM-positive cancer stem cells by repressing MYCN expression, slowing cell growth and leading to greater cell death. This finding has significant implications for decreasing cancer recurrence and curing patients.
Researchers at Duke-NUS Medical School have identified key regulators of the intestinal stem cell niche, including hormones R-spondins and Wnts. The team's study shows that subepithelial myofibroblasts are essential sources of these hormones, highlighting the close interaction between epithelial stem cells and their niche.
Researchers collected three tumor samples from a patient with salivary gland cancer, revealing a significant increase in cancer stem cells and aggressive mutations over time. This study demonstrates how tumors can adapt and overcome therapies, leading to relapse and treatment resistance.
Researchers identify dioxin receptor as a key protein controlling cancer stem cell pluripotency and tumour differentiation. The study's findings have implications for developing new therapeutic options for liver cancer and melanoma.
Researchers at UT Dallas have isolated cancer stem cells using a two-step process, marking a significant step toward developing new drugs that can target these cells. The technique uses ligands that selectively bind to breast cancer stem cells, allowing for their isolation from standard breast cancer cells.
Researchers identified a new survival pathway in cancer stem cells that fuels the growth and spread of triple-negative breast cancer. The study suggests targeting this pathway may lead to new treatments for women with this aggressive subtype of breast cancer.
Researchers at Osaka University have developed a computational method that reveals chemoresistance drug targets by integrating gene expression level and DNA methylation modification data. The approach identifies TRAF4 as an important gene for chemoresistance in gastrointestinal cancer, including esophageal cancer.
Researchers at Johns Hopkins Medicine have discovered that two proteins, COX2 and YAP1, work together to maintain bladder cancer stem cells, which cause chemotherapy resistance. Targeting these proteins may lead to improved treatment outcomes for patients with bladder cancer.
Researchers found that Hedgehog signaling proteins keep cancer stem cells alive and are required for their survival. The study suggests targeting the Hedgehog pathway could eliminate cancer stem cells and prevent recurrence.
Researchers at North Carolina State University have developed a new approach to improve cardiac stem cell therapy, which shows promise in targeting heart attack injuries and enhancing treatment effectiveness.
Researchers discovered that a medication used to treat joint and skin conditions can help people with cancer survive by increasing the survival of transplanted blood stem cells. The drug etanercept blocks TNF-a, which kills healthy cells, allowing human blood stem cells to thrive in new hosts.
A metallopeptide has been synthesized to target and disrupt mitochondrial function in breast cancer stem cells, inducing apoptosis. The peptide effectively delivers ROS and impairs mitochondrial metabolism.
A University of Houston researcher is developing a new approach to prevent esophageal cancer by targeting precursor lesions like Barrett's esophagus. By cloning stem cells from these lesions, the researcher hopes to identify drugs that can selectively kill them before they progress to cancer.
Researchers found that high ADAR1 levels correlate with reduced survival rates and disease recurrence in multiple myeloma. Inhibiting ADAR1 in experimental models suggests a potential approach to detect the disease earlier and address its root cause.
University of Illinois researchers designed nanoparticles that specifically bind to breast cancer stem cells, delivering a drug that turns off key gene pathways. The treatment significantly decreased cancer cell growth and made cancer stem cells less able to cause recurrence.
A Cornell study reveals that testicular cancer's responsiveness to chemotherapy is due to its stem cells, which are more sensitive to treatment. The research provides new insights into the basis for this phenomenon and may lead to better treatments for other cancers.
Scientists have successfully synthesized a promising anticancer molecule, BE-43547A(2), which shows unprecedented activity against pancreatic cancer stem cells. The compound reduces cancer stem cell proliferation by 21-fold and abolishes tumor-initiating capability.
A USC research team has identified a potential therapeutic target for liver cancer treatment: mitophagy, the removal of damaged mitochondria. This process can cause tumors to proliferate, but temporarily halting it may reduce cancer stem cell growth, leading to tumor regression.
Researchers used flat worms to study the role of migrating stem cells in cancer. They found that regulatory genes controlling cell migration are also essential for planarian stem cells, providing a promising model for understanding human cancers.
Researchers at Lund University have successfully isolated and studied the plant compound damsin, which inhibits the growth and spread of cancer stem cells. The study's findings suggest that damsin and its synthetic analogue ambrosin may contribute to the development of new drugs against cancer stem cells.
Scientists at the University of Freiburg have developed a new model to isolate and study cancer stem cells from breast cancer patients. The team found that inhibiting the epigenetic regulator KDM4 can block proliferation of cancer stem cells, induce changes in their molecular make-up, and reduce tumor growth.
Researchers at Lund University identified a specific marker (CD44) that interacts with protein HIF-2a, allowing cancer stem cells in glioblastoma to adapt to oxygen deprivation. This interaction enables the growth of more aggressive tumor cells, which are resistant to treatment and contribute to recurrence.
A study found that ONC201 alters the gene expression of cancer stem cells before killing tumor cells, providing a potential biomarker for response. This effect was not observed in resistant cells, suggesting a predictive gene expression signature may help forecast treatment outcomes.
Researchers identify JAK2-STAT3 cellular signaling pathway as key link between high-fat diet and tumor growth in the colon. The study provides insight into how diet influences cancer stem cell populations, potentially leading to new therapeutics.
Researchers found that grape-based compounds resveratrol and grape seed extract effectively killed colon cancer cells and suppressed tumors in mice. The combination of these compounds was found to be non-toxic to healthy cells, making them a promising approach for colon cancer prevention and treatment.
A recent study published in Nature Cell Biology identified a small RNA molecule, miR-199a, that helps maintain the activity of stem cells in both healthy and cancerous breast tissue. The microRNA promotes particularly deadly forms of breast cancer and inhibiting its effects could improve existing breast cancer therapies.
A study led by Johns Hopkins researchers found that the gene HMGA1 maintains intestinal stem cells and encourages their growth, supporting 'niche' cells. The discovery advances prospects for regenerative medicine and cancer treatments.
TET2 mutations are found in various blood cancers, including myelodysplastic syndrome and acute myeloid leukemia. The enzyme plays a crucial role in controlling gene expression, and its loss allows other genes to mutate, creating conditions for cancer to thrive.
Researchers at Washington State University have made a breakthrough in preserving sperm stem cells, which could improve fertility for boys undergoing cancer treatment. The new technology has shown an eight-fold improvement in viable sperm stem cells, allowing for potential long-term preservation and return to fertility.
Researchers at Tokyo Medical and Dental University developed a new process to improve the detection of cancer stem cells in brain tumors. The approach uses iron chelation to increase fluorescence levels, allowing for more accurate identification and removal of these cells. This breakthrough has potential to translate to clinical practice.
Researchers have devised a strategy to specifically target cancer stem cells in some cancers and reduce their tumor-generating potential. Combining Nutlin-3 and Paclitaxel showed potentiated tumor response and prevented relapse in Numb-deficient tumors, suggesting the potential of these drugs as treatment options.
Researchers at IRB Barcelona have discovered a new group of quiescent intestinal stem cells that are resistant to chemotherapy. These cells, estimated to be one in ten compared to active stem cells, play a crucial role in tissue regeneration and can produce any type of intestinal cell.
Researchers at UCLA have discovered that targeting cancer stem cells and killing tumor mass with chemotherapy drugs results in better outcomes for patients with head and neck squamous cell carcinoma. The study also found that cancer stem cells cause cervical lymph node metastasis.
Histone deacetylases are an important family of proteins regulating gene expression; altering their function can induce tumors to develop. Researchers successfully isolated HDAC using SAHA as a molecular bait, paving the way for novel cancer treatments.
Researchers at Johns Hopkins Medicine have identified a chain reaction that shields breast cancer stem cells from chemotherapy, making them resistant to treatment. The discovery could lead to the development of drugs that block this pathway, improving chemotherapy effectiveness.
UNC-Chapel Hill researchers have made a breakthrough in treating glioblastoma by using human stem cells to hunt down and kill brain cancer. The new approach shows promise for clinical trials within the next one to two years.
Researchers at Trinity College Dublin have discovered a link between the loss of miR-17 and oesophageal tumour resistance to radiotherapy. Higher numbers of cancer stem cells formed larger, more aggressive tumours and were more resistant to radiation-induced cell death. Synthetic miR-17 may enhance radiotherapy effectiveness in patients.
A study published in Science reveals a key role for the protein H1.0 in turning cancer tumor cells into cancer stem cells with the ability to sustain long-term growth and cause recurring disease outbreaks. The discovery could lead to medical interventions targeting these cells to prevent cancer spread.
A study at the University of Texas MD Anderson Cancer Center found that the tumor suppressor gene quaking (QKI) plays a major regulator role in cancer stem cells of glioblastoma, the deadliest type of brain tumor. QKI impacts cellular activity called endocytosis, allowing glioma stem cells to thrive in inhospitable sites.
A study analyzing brain tumor genomics on a single-cell level found evidence that cancer stem cells fuel the growth of oligodendrogliomas. Cancer stem cells were identified in human brain tumor samples and found to have distinct developmental signatures, suggesting they play a key role in tumor propagation.
Researchers at Sylvester Comprehensive Cancer Center have identified two leukemia-targeting drugs that could be used to treat breast and ovarian cancers by inhibiting HDACs. The study's genetically engineered cell line, BPLER, exhibited key traits associated with cancer stem cells and showed long-lasting effects of the inhibitors.
Researchers have identified RNA-based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia. The findings suggest a new way to predict leukemic relapse early and identify potential targets for new drug development.